Lawrence E. Feldman, MD
Immunotherapy has excited researchers in the field of oncology over the past few years, and a portion of patients with lung cancer have had significant benefits from this therapeutic option.
In an interview during the meeting, Feldman, associate professor, Section of Hematology/Oncology, College of Medicine, the University of Illinois Hospital and Health System, discussed first- and second-line therapy with checkpoint inhibitors in NSCLC, and the promise that emerging combinations could have on the field.
OncLive: Can you discuss your presentation on checkpoint inhibitors in NSCLC?
I was asked to speak on first- and second-line immunotherapy in lung cancer, as well as third-line and beyond. I reviewed the various trials that led to the FDA approval of first-line therapy, such as pembrolizumab in patients who express more than 50% of PD-L1 expression on their tumors.
... to read the full story